MedCap AB

MedCap AB

50.25
EUR
+0.10
(+0.20%)
1.62EPS
28.60P/E
691.58MMarket Cap
Feb 05Next Earn

Total Valuation

EUR

As of September 30, 2026, MedCap AB carries a market capitalization of 691.58M, placing it among publicly traded companies globally. Its enterprise value stands at 706.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap691.58M
Enterprise Value706.28M

Important Dates

MedCap AB's next confirmed earnings release is scheduled for February 5, 2027.

Earnings Date2/5/2027

Share Statistics

As of September 30, 2026, MedCap AB has 14.98M shares outstanding.

Shares Outstanding14.98M

Valuation Ratios

As of September 30, 2026, MedCap AB trades at a trailing price-to-earnings ratio of 28.60. The price-to-sales ratio is 3.38, and the price-to-book ratio stands at 4.59.

PE Ratio28.60
PS Ratio3.38
PB Ratio4.59
P/TBV Ratio24.99
P/FCF Ratio22.22
P/OCF Ratio18.59

Enterprise Valuation

As of September 30, 2026, MedCap AB trades at an EV/EBITDA multiple of 13.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. MedCap AB trades at an EV/FCF ratio of 19.93, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 706.28M versus a market cap of 691.58M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.45
EV / EBITDA13.61
EV / EBIT19.96
EV / FCF19.93

Financial Position

As of September 30, 2026, MedCap AB maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.60, indicating elevated leverage, while an interest coverage ratio of 9.49 demonstrates adequate ability to service its debt obligations.

Current Ratio1.71
Quick Ratio0.45
Debt / Equity25.60
Debt / EBITDA0.74
Interest Coverage9.49

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, MedCap AB posted a return on equity (ROE) of 17.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.76 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.23, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.76, useful for judging operating efficiency across full business cycles. The company generates approximately 321,423.46 in revenue per employee across its workforce of 637.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.00 indicates how many times MedCap AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)17.91
Return on Assets (ROA)11.23
Return on Invested Capital (ROIC)15.76
Return on Capital Employed (ROCE)16.76
Revenue Per Employee321,423.46
Employee Count637.00
Inventory Turnover3.00

Taxes

EUR

Over the twelve months ended September 30, 2026, MedCap AB recorded 6.83M in income tax expense. That works out to an effective tax rate of 21.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 31.08M, leaving 24.21M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax6.83M
Effective Tax Rate21.97

Stock Price Statistics

EUR

As of the close on November 17, 2026, MedCap AB's stock has gained approximately 2.87% over the past 52 weeks. The 50-day moving average sits at 48.20, while the 200-day moving average is 47.31.

52-Week Price Change2.87%
50-Day Moving Average48.20
200-Day Moving Average47.31

Income Statement

EUR

Over the twelve months ended September 30, 2026, MedCap AB generated 204.75M in revenue and converted that into 24.21M in net income, yielding earnings per share of 1.62. EBITDA reached 51.89M, while operating income came in at 35.40M.

Revenue204.75M
Gross Profit122.04M
Operating Income35.40M
Pretax Income31.08M
Net Income24.21M
EBITDA51.89M
EBIT35.39M
Earnings Per Share (EPS)1.62

Balance Sheet

EUR

As of September 30, 2026, MedCap AB holds 24.07M in cash and equivalents against 38.62M in total debt, resulting in a net debt position of -6.93M. Total book value stands at 150.67M, with working capital of 37.40M providing operational flexibility.

Cash & Cash Equivalents24.07M
Total Debt38.62M
Net Debt-6.93M
Equity (Book Value)150.67M
Book Value Per Share10.06
Working Capital37.40M

Cash Flow

EUR

MedCap AB produced 37.23M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -6.07M in capital expenditures, free cash flow totaled 31.16M - equivalent to 2.08 per share.

Operating Cash Flow37.23M
Capital Expenditures-6.07M
Free Cash Flow31.16M
FCF Per Share2.08

Margins

Over the twelve months ended September 30, 2026, MedCap AB posted a gross margin of 59.61, reflecting its pricing power and cost economics. The operating margin of 17.29 and net profit margin of 11.82 provide insight into operational efficiency.

Gross Margin59.61
Operating Margin17.29
Pretax Margin15.18
Profit Margin11.82
EBITDA Margin25.34

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 4.50, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MedCap AB shareholders.

Shareholder Yield2.84
FCF Yield4.50

Stock Splits

MedCap AB's most recent stock split took place on September 27, 2016 with a 10:1 split ratio.

Last Split Date9/27/2016
Split Ratio10:1